Vertex Pharma: Why I Am Buying This Dip

Vertex Pharmaceuticals (NASDAQ: VRTX ) reported better than expected earnings on the 4th of November with the stock surging over 5%. The company beat both revenue and earnings estimates, while raising its 2024 guidance, as sales increased 12% on a year-over-year basis. The short-lived rallyBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (T ...